Summary
Experts recommend that the Pharmaceutical Benefits Scheme (PBS) fund Triptorelin for unrestricted use in treating breast cancer, endometriosis, and gender dysphoria. This recommendation follows AstraZeneca's announcement to remove Zoladex from the market, which would leave thousands of women without alternative treatment.